Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Á÷Àå¼öÁö°Ë»ç À½¼ºÀ̸鼭 Ç÷û Àü¸³¼±Æ¯ÀÌÇ׿øÀÌ 4-10ng/§¢ÀΠȯÀÚ¿¡¼­ Àü¸³¼± »ý°ËÀÇ ÀÇÀÇ The Effectiveness of Prostate Biopsy in Patients with Negative Digital Rectal Examination and Serum Prostate Specific Antigen Concentration between 4 and 10ng/§¢

´ëÇѺñ´¢±â°úÇÐȸÁö 1999³â 40±Ç 7È£ p.853 ~ 857
¹Î¿µ±â, À̸í¼ö, ¼ÛÁÖÈï,
¼Ò¼Ó »ó¼¼Á¤º¸
¹Î¿µ±â (  ) 
¿ø±¤´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

À̸í¼ö (  ) 
¿ø±¤´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç
¼ÛÁÖÈï (  ) 
¿ø±¤´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

Abstract

°á·Ð
DRE À½¼ºÀ̸鼭 Ç÷û PSAÄ¡ ȸ»ö ¹üÀ§·Î Áõ°¡ÇÑ È¯ÀÚ¿¡¼­ Àü¸³¼±¾ÏÀÇ ¹ß°ßÀ²À» Á¶»çÇÑ
°á°ú 37%(±¹³» ¹®Çå °íÂû Áõ·Ê Æ÷ÇÔ ½Ã 43%)·Î ¼­±¸¿¡¼­ÀÇ 30%¿¡ ºñÇØ ÇöÀúÈ÷ ³·¾Ò´Ù. µû
¶ó¼­ ¼­±¸¿¡¼­¿Í °°ÀÌ ÀÌ·± ¸ðµç ȯÀÚ¿¡¼­ ºñ¿ëÀÌ ¸¹ÀÌ µé°í ħ½ÀÀûÀÎ Àü¸³¼± »ý°ËÀ» ½ÃÇà
ÇÏ´Â °ÍÀº ½Ã°£, °æÁ¦ÀûÀÎ Ãø¸é¿¡¼­ ºñÈ¿À²ÀûÀÎ °ÍÀ¸·Î ÆǴܵȴÙ.
Ç÷û PSAÄ¡°¡ PSA>10ng/§¢ÀÏ ¶§´Â ¼­±¸ÀÇ Ç÷û PSAÄ¡ ȸ»ö ¹üÀ§¿Í ºñ½ÁÇÑ Àü¸³¼±¾Ï
¹ß°ßÀ²À» º¸À̹ǷΠ¼­±¸¿Í °°ÀÌ Àû±ØÀûÀÎ Àü¸³¼± »ý°ËÀÌ ÇÊ¿äÇÒ °ÍÀ¸·Î »ý°¢µÇ°í ¾Æ¿ï·¯ ¿Ö
ÀÌ·¯ÇÑ °á°ú°¡ ³ª¿Ô´ÂÁö¿¡ ´ëÇÑ ¿øÀÎ Á¶»çµµ ÀÌ·ïÁ®¾ß ÇÒ °ÍÀ¸·Î »ý°¢µÈ´Ù.

Purpose: Most urologists, to our knowledge, recommend prostatic biopsy if serum
prostate specific antigen(PSA) concentrations are between 4 and 10 ng/§¢(gray zone),
even in the abscence of abnormal digital rectal examination (DRE). But the detection of
prostate cancer has not been frequent in patients with negative DRE and gray zone of
serum PSA. So, we investigated the detection rate of prostate cancer to evaluate the
effectiveness of biopsy, and provide the clinical data which is needed to make an
appropriate guideline for management in those patients in korea.
Materials and Methods: We retrospectively reviewed 58 patients with negative DRE
and serum PSA greater than 4ng/§¢, in whom transrectal systemic biopsy was done
between January 1, 1996 and July 31, 1998. Additionally we analysed 38 patients with
negative DRE and serum PSA more than 4ng/§¢ in a Korean literature. We calculated
the detection rate of prostate cancer in patients with gray zone of serum PSA and
serum PSA greater than 10ng/§¢, respectively.
Results: Prostate cancer was detected in 5 patients out of the 58 patients (8.6%),
including 1 patient(3.7%) out of 27 patients with gray zone of serum PSA and 4(12.9%)
out of 31 patients with serum PSA greater than 10ng/§¢. Prostate cancer was detected
in 4 patients out of the 38 patients in the literature(10.5%), including 1 patient(5.0%) out
of 20 patients with gray zone of serum and 3 patients(16.7%) out of 18 patients with
serum PSA greater than 10ng/§¢. Combining the results of our current study with that
of other Korean literature, total number of patients was 96, and 9(9.4%) of them proved
to harbor prostate cancer, including 2 patients(4.3%) out of 47 patients with gray zone
of serum PSA and 7 patients(14.3%) out of 49 patients with serum PSA greater than
1.0ng/§¢.
Conclusions: The detection rate of prostate cancer in Korean with negative DRE and
gray zone of serum PSA is significantly lower than that in North American. Therefore
it may not be effective to perform biopsy in all of those patients in Korea. Needed are
Korean criteria of prostatic biopsy to detect prostate carcinoma in those patients, which
can be acceptable in Korean.

Å°¿öµå

Prostate cancer; ORE; PSA; Biopsy; Gray zone;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS